-
NEWS: New research identifying the number of women at risk of FNAIT to be presented at ASHG 2024
Rallybio, a clinical-stage biotechnology company, will be presenting the findings of a genetic database analysis study conducted in partnership with HealthLumen on Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) risk across racially and ethnically diverse populations at the American Society of Human Genetics (ASHG) 2024 Annual Meeting. The conference will take place from November 5–9 2024 in Denver, Colorado.
-
Supporting rare disease patient advocacy with epidemiological insights
Awareness of the vast impact of rare diseases, which affect approximately 300 million people globally (1), has significantly increased over the years, leading to increased funding and investment in rare disease research and therapy development. Although more than half of the novel drug approvals by the FDA’s Center for Drug Evaluation and Research last […]
-
The role of precision epidemiology in R&D decision-making: Spotlight on rare genetic diseases
Rare genetic diseases are challenging to treat due to their complexity, the unique nature of each condition, and the – by definition – small numbers of patients affected by each one. Encouragingly for the rare disease community, the field is moving rapidly with a wide variety of innovative therapies being developed, including gene therapy involving […]
